key: cord-0826118-gbxlkxit authors: Manohar, C.; Sun, J.; Schlag, P.; Santini, C.; Fontecha, M.; Lotscher, P.; Bier, C.; Goepfert, K.; Duncan, D.; Spier, G.; Jarem, D.; Kosarikov, D. title: Agile design and development of a high throughput cobas(R) SARS-CoV-2 RT-PCR diagnostic test date: 2021-10-18 journal: nan DOI: 10.1101/2021.10.13.21264919 sha: 659dfbc9d274e4af26b3395bc06fbc4e2fd8f3b7 doc_id: 826118 cord_uid: gbxlkxit Diagnostic testing is essential for management of the COVID-19 pandemic. An agile assay design methodology, optimized for the cobas(R) 6800/8800 system, was used to develop a dual-target, qualitative SARS-CoV-2 RT-PCR test using commercially available reagents and existing sample processing and thermocycling profiles. The limit of detection was 0.004 to 0.007 TCID50/mL for USA-WA1/2020. Assay sensitivity was confirmed for SARS-CoV-2 variants Alpha, Beta, Gamma, Delta and Kappa. The coefficients of variation of the cycle threshold number (Ct) were between 1.1 and 2.2%. There was no difference in Ct using nasopharyngeal compared to oropharyngeal swabs in universal transport medium (UTM). A small increase in Ct was observed with specimens collected in cobas(R) PCR medium compared to UTM. In silico analysis indicated that the dual-target test is capable of detecting all >1,800,000 SARS-CoV-2 sequences in the GISAID database. Our agile assay design approach facilitated rapid development and deployment of this SARS-CoV-2 RT-PCR test. Diagnostic testing is essential for management of the COVID- 19 pandemic. An agile assay 20 design methodology, optimized for the cobas® 6800/8800 system, was used to develop a dual-21 target, qualitative SARS-CoV-2 RT-PCR test using commercially available reagents and existing 22 sample processing and thermocycling profiles. The limit of detection was 0.004 to 0.007 23 TCID 50 /mL for USA-WA1/2020. Assay sensitivity was confirmed for SARS-CoV-2 variants 24 Alpha, Beta, Gamma, Delta and Kappa. The coefficients of variation of the cycle threshold 25 number (Ct) were between 1.1 and 2.2%. There was no difference in Ct using nasopharyngeal 26 compared to oropharyngeal swabs in universal transport medium (UTM). A small increase in Ct 27 was observed with specimens collected in cobas® PCR medium compared to UTM. In silico 28 analysis indicated that the dual-target test is capable of detecting all >1,800,000 SARS-CoV- 2 29 sequences in the GISAID database. Our agile assay design approach facilitated rapid 30 development and deployment of this SARS-CoV-2 RT-PCR test. 31 4 Early in the pandemic only a few SARS-CoV-2 genomic sequences were available in public 54 databases (e.g. GISAID or NCBI). When the cobas® SARS-CoV-2 test was designed in early 55 2020 , little was known about what regions of the genome might be subject to sequence variation 56 and/or recombination. Despite the paucity of knowledge about potential sequence variation, we 57 designed a single well, dual-target assay to detect SARS-CoV-2-specific sequences using targets 58 in the non-structural region of the ORF1a/b locus, and a conserved region in the structural 59 envelope (E)-gene common to all sarbecoviruses, including SARS-CoV-2. The test was designed 60 to meet the need for high throughput testing on the cobas 6800/8800 system, which performs 61 fully automated sample preparation, real time RT-PCR reaction setup, target amplification and 62 detection. 63 SARS-CoV-2 can evolve in response to external selection pressures. Strong but incomplete 64 inhibition of replication, which might occur in an infected person with partial immunity, can 65 result in the selection of SARS-CoV-2 variants that have higher replicative fitness than the wild-66 type virus in a population of susceptible hosts. Similarly, if a naturally occurring variant were to 67 arise with increased ability to spread in an immunologically naïve population, it could out-68 compete the wild-type virus in a relatively short period of time. The emergence of several 69 "variants of concern" (VOC) and "variants of interest" in many different locations of the world 70 in recent months is therefore not unexpected, and has several important public health and clinical 71 implications (10) (11) (12) (13) (14) (15) (16) shown to be equivalent to natural nasopharyngeal matrix in assay performance (data not shown). 87 Virus stocks for variants of concern were obtained from BEI Resources (catalog numbers NR-88 54000, NR-54008, NR-54982, NR-55611, NR-55486, NR-55308, NR-55309, NR-55439, NR-89 55469, and NR-55654). For the wild-type strain, genomic RNA was used (NR-52499). Virus 90 RNA concentration was determined by droplet digital PCR. 91 At the time when the cobas SARS-CoV-2 test was designed (January 2020), only seven SARS-159 CoV-2 sequences were available from the Global Initiative on Sharing All Influenza Data 160 (GISAID). To guard against the possibility that viral sequence changes in the target site may 161 negatively impact detection, two complementary strategies were employed. First, a dual target 162 design was chosen, which dramatically increases the likelihood of viral sequence detection and 163 PCR signal preservation from one of the two targets even if the other has sequence variations. 164 Second, selection of target regions where sequences are conserved between virus species (e.g. 165 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 18, 2021. ; between SARS-CoV-2 and SARS-CoV) greatly enhances the chance that this sequence will remain conserved within species. We selected one target (Target 1) in the ORF1a/b coding 167 region that is highly specific for SARS-CoV-2. The second target (Target 2) is located in a 168 region of the E gene that is conserved among sarbecoviruses (Fig. 1) . A proprietary software 169 program, AAD (see Methods), was used to evaluate the seven available SARS-CoV-2 sequences 170 and over 1000 sequences from other sarbecoviruses, including SARS-CoV, that were available 171 from NCBI. Target 2 positivity can be interpreted unambiguously given the clinical and 172 epidemiological context (i.e. with knowledge that SARS-CoV-2 is circulating but SARS-CoV is 173 not). 174 In June 2021, an updated in silico analysis of 1,874,933 SARS-CoV-2 sequences in the GISAID 176 database was performed. Table 1 summarizes the predicted impact of sequence variation at 177 primer or probe binding sites for variants represented in at least 0.02% (403 or more) of all 178 SARS-CoV-2 sequences in the GISAID database (a complete listing of all variants including 179 very infrequent sequences can be found in the Supplemental Data Table S1 ). A summary of the 180 numbers of individual haplotypes (defined as a specific sequence including the four primer and 181 two probe binding sites) is shown in Table 2 . Overall, 98.56% of sequences have no changes in 182 primer or probe binding sites at either target, and 1.4% have only a single change. One of these 183 (variant 13, found in 0.025% of sequences), which has a single change in the probe binding site 184 for Target 2 (Table 1) , is predicted to reduce the reactivity of single probes or primers, and has 185 been previously shown to be associated with failure of detection at Target 2 (22) . An additional 186 74 (0.004%) sequences, bearing between two and eight nucleotide changes, were observed that 187 are predicted to impact assay performance for target 1 (n=31) or target 2 (n=43; Assay sensitivity was determined by replicate testing of serial dilutions of USA-WA1/2020 193 virus. As shown in Table 3 Assay sensitivity for SARS-CoV-2 variants of concern alpha, beta, gamma, and delta (B. Table 5 . Coefficients of 217 variation of less than 2.0% CV were observed for all variables and concentration levels. Slightly 218 more variability was observed between reagent lots and in the within-run residual category. 219 Precision values of 0.8% CV or less were observed between instruments, day-to-day, and run-to-220 run. Overall, the coefficients of variation ranged from 1.1 to 1.9% for Target 1, and from 1.1 to 221 2.2% for Target 2. higher than the LoD. The cycle threshold number (Ct, inversely correlated with RNA quantity in 228 the specimen) from replicate tests for each target is shown in Fig. 2 types of swabs and collection media. Ct values for specimens diluted in CPM were slightly 233 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The paucity of sequence data at the early stages of an outbreak is a significant challenge for 255 molecular test development (23, 24) . The cobas SARS-CoV-2 test primers and probes were 256 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 18, 2021. ; https://doi.org/10.1101/2021.10.13.21264919 doi: medRxiv preprint designed at a time when only seven genomic sequences were publicly available. However, 257 sequence conservation may be predicted by considering data from related viruses for which more 258 sequences have been characterized. A region of conserved sequence across different virus 259 species is also likely to remain conserved within a species in the future. 260 Our approach included two different sets of primers and probes, one of which (Target 1) is 261 specific for ORF1a/1b of SARS-CoV-2, while the other (Target 2) is intended to react with E-262 gene sequences of SARS-CoV-2, SARS-CoV, and other sarbecoviruses that infect bats. The 263 genes in which the targets should be located were not pre-determined, but instead the AAD 264 approach identified sites anywhere in the genome predicted to provide the best performance and 265 desired level of sequence conservation. While Target 2 reactivity is expected for both SARS-266 CoV and SARS-CoV-2, virus positivity can be unambiguously established with knowledge of 267 extant virus and disease prevalence, and in combination with the SARS-CoV-2 specific Target 1 268 result. Importantly, the use of two targets enables test accuracy even in the presence of sequence 269 variation in one of the two target sequences. This has been demonstrated to occur in at least one 270 case (22) . 271 The limit of detection of the cobas SARS-CoV-2 test was determined to be between 0.004 and 272 0.007 TCID 50 /mL or between 30 and 52 copies/mL for the particular virus stock used here. It 273 should be noted that the relationship between TCID 50 (or plaque forming units) and number of 274 RNA copies may differ between virus preparations; this may explain small differences in LoD 275 reported in RNA copies/mL elsewhere (25) . A lower LoD for the E-gene target compared to 276 other targets has been reported previously (26) , which is consistent with our results. We noted 277 that at low virus input levels, Target 1 positivity is impacted more than Target 2, in spite of 278 higher Ct values for Target 2. 279 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 18, 2021. ; https://doi.org/10.1101/2021.10.13.21264919 doi: medRxiv preprint SARS-CoV-2 RT-PCR assays using NPS, OPS or other specimen types (27) (28) (29) (30) (31) (32) (33) (34) . Our results 281 support the use of either NPS or OPS as the specimen type, since there was no difference in the 282 ability to detect SARS-CoV-2 RNA spiked into either specimen at low levels. While NPS is 283 viewed as the gold standard for many respiratory pathogens, OPS are easier to obtain and less 284 intrusive for the patient. These findings should be confirmed with specimens from infected 285 individuals in the clinic. 286 In the early phases of the COVID-19 pandemic, many clinicians experienced a shortage of 287 recommended sample collection materials including media for specimen storage and shipping. 288 Our data indicate equivalent sensitivity of the cobas SARS-CoV-2 test when specimens are 289 stored in UTM, CPM or saline, as long as specimens are refrigerated (2-8 ˚C) and stored for 6 290 days or less. CPM has the added advantage of inactivating the infectivity of SARS-CoV-2, thus 291 improving biosafety for specimen handling in the laboratory (21) . 292 Several independent studies have reported on the performance of the cobas SARS-CoV-2 test, in 293 comparison with laboratory-developed tests (LDTs) or other commercial assays. Generally, 294 overall percent agreement values range from 95 to 99% (25, 26, (35) (36) (37) , with more discordance 295 observed in specimens with low viral loads (35, 36, 38) . 296 In conclusion, the cobas SARS-CoV-2 is a robust, sensitive and specific test for qualitative 297 diagnosis of infection by SARS-CoV-2 that can be performed using equipment and infrastructure 298 already widely available in clinical reference laboratories globally. The rapid development and 299 deployment of this test was made possible by the application of the AAD approach and early 300 availability of sequence information and reference reagents. 301 302 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 18, 2021. ; https://doi.org/10.1101/2021.10.13.21264919 doi: medRxiv preprint Table 1 Analysis of cobas SARS-CoV-2 primer and probe binding site sequence variation. Table S1 . ** This variant confirmed experimentally to reduce Target 2 (but not Target 1) reactivity (22) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Threshold Cycle Number (Mean +/-SD) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 18, 2021. ; All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. China Novel Coronavirus I, Research T. 2020. A Novel Coronavirus from Patients with Pneumonia in China An interactive web-based dashboard to track COVID-19 in real time Clinical Characteristics of Coronavirus Disease 2019 in China Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding The cobas(R) 6800/8800 System: a new era of automation in molecular diagnostics Genetic Variants of SARS-CoV-2-What Do They Mean? Abrahams characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations Updated rapid risk assessment from ECDC on the risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA -first update Emergence of SARS-CoV-2 B.1.1.7 Lineage -United States SARS-CoV-2 variants, spike mutations and immune escape GISAID: Global initiative on sharing all influenza data -from vision to reality The thermodynamics of DNA structural motifs MELTING, a flexible platform to predict the melting temperatures of nucleic acids Pushing beyond specifications: Evaluation of linearity and clinical performance of the cobas 6800/8800 SARS-CoV-2 RT-PCR assay for reliable quantification in blood and other materials outside recommendations A Recurrent Mutation at Position 26340 of SARS-CoV Is Associated with Failure of the E Gene Quantitative Reverse Transcription-PCR Utilized in a Commercial Dual-Target Diagnostic Assay Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche Comparison of commercial assays and laboratory developed tests for detection of SARS-CoV-2 Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test Nasopharyngeal Swabs Are More Sensitive Than Oropharyngeal Swabs for COVID-19 Diagnosis and Monitoring the SARS-CoV-2 Load Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously Evaluation of Transport Media and Specimen Transport Conditions for the Upper respiratory tract sampling in COVID-19 Value of swab types and collection time on SARS-COV-2 detection using RT-PCR assay Sensitivity of nasopharyngeal, oropharyngeal, and nasal wash specimens for SARS-CoV-2 detection in the setting of sampling device shortage Detection profile of SARS-CoV-2 using RT-PCR in different types of clinical specimens: A systematic review and meta-analysis Comparison of Two High-Throughput Reverse Transcription-PCR Systems for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2